CDC Interim Estimates Find Moderna Vaccines Most Effective Against Delta Breakthroughs

September 15, 2021 by Reece Nations
CDC Interim Estimates Find Moderna Vaccines Most Effective Against Delta Breakthroughs
The CDC′s Tom Harkin Global Communications Center located on the organization′s Roybal Campus in Atlanta, Georgia. (Photo Credit: James Gathany, Centers for Disease Control and Prevention)

WASHINGTON — Data collected by the Centers for Disease Control and Prevention on COVID-19’s delta variant found that vaccine efficacy was higher among recipients of the Moderna vaccination at 95%, higher than both the Pfizer-BioNTech and the Johnson & Johnson vaccines.

The CDC collected data in a multistate interim analysis of 32,867 medical encounters from a wide range of adults between June and August. In its findings, the CDC found that recipients of the Pfizer vaccine demonstrated 80% effectiveness at preventing breakthrough infection while the J&J vaccine showed 60% effectiveness.

Patients who had not received any COVID-19 vaccine doses were considered unvaccinated, and those who had received one mRNA dose only or their second dose fewer than 14 days before testing or the encounter date were excluded from the study. Out of the adults in the study who experienced emergency department or urgent care visits for “COVID-19–like [illnesses],” positive cases were identified among 7% of fully vaccinated patients and 28.9% of unvaccinated patients.

“[Vaccine effectiveness] was adjusted for age, geographic region, calendar time, and virus circulation, and weighted for inverse propensity to be vaccinated or unvaccinated,” CDC officials said in the report. “[Vaccine effectiveness] estimates with 95% confidence intervals that did not overlap were considered statistically different. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.”

The CDC utilized the “VISION Network” to examine medical encounters from 187 hospitals and 221 emergency departments and urgent care clinics across nine states starting on the date when the delta variant accounted for over 50% of COVID-19 cases in each medical facility’s respective state. Vaccination status of the patients in the study was documented in electronic health records and immunization registries.

The VISION Network is comprised of Columbia University Irving Medical Center in New York, HealthPartners in Minnesota and Wisconsin, Intermountain Healthcare in Utah, Kaiser Permanente Northern California, Kaiser Permanente Northwest in Oregon and Washington, Regenstrief Institute in Indiana and the University of Colorado. The median age of patients in the study was 43 years, and the interquartile range was between 29 and 62 years old.

“The findings in this report are subject to at least three limitations,” CDC officials said in the report. “First, [vaccine effectiveness] by time since vaccination was not examined; further evaluation of possible waning of vaccine protection is currently underway. Second, [vaccine effectiveness] for partial vaccination was not assessed. Finally, although the facilities in this study serve heterogeneous populations in nine states, the findings might not be generalizable to the U.S. population.”

Overall vaccine effectiveness estimates were roughly equivalent to those during the months before the delta variant became predominant in the country, although their effectiveness among adults older than 75 years was lower than adults younger than 75 years. This discrepancy in effectiveness by age “should be interpreted with caution” and could be related to mutations of the virus, waning immunity over the course of time or a combination of factors.

Vaccine effectiveness against emergency department and urgent care clinic encounters overall was 82%, and effectiveness against COVID-19 hospitalization was 86%, according to the CDC’s report. The CDC concluded in its report that further examination of the “magnitude and sources of product-specific” differences in vaccine effectiveness is warranted.

“These findings reaffirm the high protection of COVID-19 vaccines against moderate and severe COVID-19 resulting in [emergency department], [urgent care], and hospital visits and underscore the importance of full COVID-19 vaccination and continued benefits of COVID-19 vaccination during Delta variant predominance,” CDC officials said in the report. 

A+
a-
  • Centers for Disease Control
  • Delta Variant
  • vaccines
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top